Repositioning Candidate Details
| Candidate ID: | R0910 |
| Source ID: | DB05974 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Transcrocetinate |
| Synonyms: | 8,8'-diapo-8,8'-carotenedioic acid; 8,8'-diapo-ψ,ψ-carotenedioic acid; 8,8'-diapocarotenedioic acid; Crocetin; trans-crocetin |
| Molecular Formula: | C20H24O4 |
| SMILES: | C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O |
| Structure: |
|
| DrugBank Description: | Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma. |
| CAS Number: | 27876-94-4 |
| Molecular Weight: | 328.408 |
| DrugBank Indication: | Investigated for use/treatment in cancer/tumors (unspecified), hemorrhage, hypoxia, respiratory failure, and strokes. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Trans sodium crocetinate is a novel drug, which has been shown to increase whole-body oxygen consumption during hemorrhagic shock. It works by increasing the diffusion rate of oxygen through plasma rather than on a specific symptom of hemorrhagic shock and has been suggested as a general treatment for hypoxemia. Thus it could also be beneficial for treating respiratory insufficiencies. |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I16 | 6713 | Cerebrovascular disease | An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain. http://en.wikipedia.org/wiki/Cerebrovascular_disease, http://www.ncbi.nlm.nih.gov/books/NBK378/ | disease of anatomical entity/ cardiovascular system disease/ vascular disease/cerebrovascular disease | Details |